secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0000950170-25-038703
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma reports year-end 2024 cash of $75.1M; Phase 3 topline data due Q3 2025
--------------------------------------------------------------------------------

- Cash, equivalents and investments $75.1M as of Dec 31, 2024; raised ~$18.8M via ATM after quarter-end.
- Phase 3 EFZO-FIT enrollment complete (268 patients); topline pulmonary sarcoidosis data expected Q3 2025.
- Fourth positive DSMB review; FDA meeting finalized SAP on steroid reduction endpoint.
- Phase 2 EFZO-CONNECT interim data for scleroderma-ILD expected Q2 2025.
- R&D expenses $54.4M, G&A $13.8M for FY2024; cash runway extends one year past Phase 3 readout.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017025038703/0000950170-25-038703-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017025038703/atyr-20240314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-038703

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer